Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility and Efficacy of Transvaginal Botulinum Toxin A Chemodenervation of the Bladder for the Third Line Treatment of Refractory Overactive Bladder

NCT05463822 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05463822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility and Efficacy of Transvaginal Botulinum Toxin A Chemodenervation of the Bladder for the Third Line Treatment of Refractory Overactive Bladder
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2019
Completion date
September 27, 2021
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder, overactive, overactive bladder, urge incontinence, urgency urinary, urinary frequency/urgency